A5049966045- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- Health Systems, Economic Evaluations, Quality of Life
- HER2/EGFR in Cancer Research
- Systemic Sclerosis and Related Diseases
- Ovarian cancer diagnosis and treatment
- Intraperitoneal and Appendiceal Malignancies
- Brain Metastases and Treatment
- Medical and Biological Sciences
- Urticaria and Related Conditions
- Estrogen and related hormone effects
- Traumatic Ocular and Foreign Body Injuries
- Advanced NMR Techniques and Applications
- Facial Trauma and Fracture Management
- Dupuytren's Contracture and Treatments
- Nutrition, Genetics, and Disease
- Venous Thromboembolism Diagnosis and Management
- Cancer Genomics and Diagnostics
- Patient-Provider Communication in Healthcare
- Dermatological and Skeletal Disorders
- Ultrasound in Clinical Applications
- Glaucoma and retinal disorders
United States Food and Drug Administration
2020-2024
Center for Drug Evaluation and Research
2020-2024
Food and Drug Administration
2021
George Washington University
2015-2018
Drexel University
2016
Katowice School of Technology
2015
The US Food and Drug Administration (FDA) approved elacestrant for the treatment of postmenopausal women or adult men with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), 1 (
Background: Patient reports of expected treatment side effects are increasingly collected as part the assessment patient experience in clinical trials. A global effect item that is patient-reported has potential to inform overall tolerability. Therefore, aim this study was examine completion and distribution such a single-item measure burden five cancer Methods: Data from trials internal Food Drug Administration databases included Functional Assessment Cancer Therapy–General (i.e. impact on...
Oncology clinical trials terms and definitions have become increasingly complex, which has led to shortcomings among research staff healthcare providers in informing trial participants with the study results consenting procedures simple language. Understanding oncology is of critical importance assist patients caregivers making cancer treatment decisions, including enrollment into trials. The U.S. Food Drug Administration's (FDA) Center Excellence (OCE) organized a physician patient...
Leptomeningeal carcinomatosis is a condition in which metastatic cancer cells infiltrate the meninges of brain and spinal cord, progressing to also involve cerebrospinal fluid. Incidence leptomeningeal arising from an esophageal particularly rare. Here, we present case report 76-year-old Caucasian man with history adenocarcinoma status-post chemoradiation followed by resection. He was admitted our unit for intractable headache, nausea without emesis, anorexia, weakness, gait instability,...
e13507 Background: Cancer genetic testing guides disease surveillance in those with moderate to high cancer risk and serves as a tool for personalized medicine diagnosed cancer. Primary care specialist providers are directly involved the identification of individuals suitable counseling (GCT) susceptibility, but familiarity breadth complexity among is not well described. This study assessed physicians' knowledge genetics awareness services at single academic institution. Methods: A...
Abstract Cancer prevention is a global public health challenge that requires multidisciplinary approach including biology, epidemiology, medicine, nutrition, education, clinical trials and policy. An intent-to-treat analysis of randomized controlled trial differs from in the observational setting, therefore, it important to understand underlying disease process aspects intervention through research. The genetic heterogeneity some cancers strongly support an enhanced focus on as strategy...
1055 JJG, JC, TMP contributed equally. JAB, LAK Background: Cyclin dependent kinase 4/6 inhibitors (CDKIs) are oral targeted agents approved for use in combination with endocrine therapy as first or second line treatment of hormone-receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced metastatic breast cancer. We previously reported the pooled analyses progression-free survival patients certain clinicopathologic subgroups, and results showed a consistent...
Background: Cyclin dependent kinase 4/6 inhibitors (CDKIs) are oral targeted agents approved for use in combination with endocrine therapy as 1st or 2nd line treatment of hormone-receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced metastatic breast cancer. We previously reported the pooled analyses progression-free survival (PFS) patients certain clinicopathological subgroups, all whom received consistent benefit from addition a CDKI to hormonal...